Multivalent S2-based vaccines may offer broad protection against various SARS-CoV-2 variants and related coronaviruses.
NIH, Japan Agency for Medical Research and Development, Garry Betty/ V Foundation Chair Fund, and NSF.
Halfmann et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: